Search

Your search keyword '"Zieniewicz K"' showing total 19 results
Start Over Author "Zieniewicz K" Topic humans
19 results on '"Zieniewicz K"'

1. Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study

Author

Rystedt, J.M.L., Kleeff, J., Salvia, R., Besselink, M.G., Prasad, R., Lesurtel, M., Sturesson, C., Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B.A., Boonstra, E.A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., Gelder, A. de, Rose, A.M. de, Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T.K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K.H., Hartman, V., Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, B., Jonas, E., K.A., Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V., Lucidi, V., Mabrut, J.Y., Mansson, C., Mieog, S., Mirza, D.F., Oldhafer, K.J., Omoshoro-Jones, J.A.O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R.J., Poves, I., Calvo, M.P., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A.K., Smith, M.D., Silva, D.S., Sparrelid, E., Stattner, S., Stavrou, G.A., Straka, M., Stromberg, C., Sutcliffe, R.P., Szijarto, A., Taflin, H., Trotovsek, B., Gulik, T. van, Wallach, N., Zieniewicz, K., European-African HepatoPancreato, Skane University Hospital [Lund], Fachbereich Physik [Halle-Saale], Martin-Luther-Universität Halle Wittenberg (MLU), Azienda Ospedaliera Universitaria Integrata of Verona, University of Amsterdam [Amsterdam] (UvA), St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Karolinska University Hospital [Stockholm], University of Southampton, Policlinico di Monza, Partenaires INRAE, Universita 'La Sapienza' Roma (Istituto CNR), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Catholic University, Rome, Italy, Complexo Hospitalario Universitario de Vigo, Ghent University Hospital, Linköping University (LIU), Universiteit Leiden [Leiden], University Medical Center Groningen [Groningen] (UMCG), Universiteit Antwerpen [Antwerpen], Universidad de Murcia, J. G. Mendel Cancer Center Novy Jicin, Universidad de Salamanca, Hospital Dr Josep Trueta de Girona, Izmir University, TURKEY, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto, University of Ljubljana, University of Warsaw (UW), İZMİR EGE University Medical Faculty Hospital, Univeristà di Genova, Semmelweis University of Medicine [Budapest], University of Dublin, Universidad de Deusto [Bilbao] (DEUSTO), Universidad de Deusto (DEUSTO), Hospital Universitario Cruces = Cruces University Hospital, Hadassah Hebrew University Hospital, The Hebrew University of Jerusalem (HUJ), Catholic University of Rome, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Queens Elizabeth Hospital [Birmingham], University of Iceland [Reykjavik], Community Hospital of horn, Umeå University, University Hospital Motol [Prague], Uppsala Universitet [Uppsala], University of Cape Town, Hadassah Hebrew University Medical Center [Jerusalem], Community Hospital Horn, CHU Amiens-Picardie, Vrije Universiteit Brussel (VUB), Université de Lyon, Asklepios Klinik Barmbek, University of Johannesburg (UJ), Vall d'Hebron University Hospital [Barcelona], Facultad de Medicina [Zaragoza], University of Zaragoza - Universidad de Zaragoza [Zaragoza], Cerrahpasa Medical Faculty, University of Catania [Italy], IMIM-Hospital del Mar, Generalitat de Catalunya, Innsbruck Medical University [Austria] (IMU), Unité Expérimentale Recherches Intégrées - Gotheron (UERI), Institut National de la Recherche Agronomique (INRA), University of Pristina-Kosovo, Peja/Pec Hospital, Sahlgrenska Academy at University of Gothenburg [Göteborg], Universidad de Málaga [Málaga] = University of Málaga [Málaga], University Hospital Düsseldorf, Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Manchester Royal Infirmary, University of Manchester [Manchester], Chris Hani Baragwanath Hospital, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), European-African HepatoPancreato, Ege Üniversitesi, Groningen Institute for Organ Transplantation (GIOT), Surgery, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and Quality of Life, and AGEM - Endocrinology, metabolism and nutrition

Subjects
INTRAOPERATIVE CHOLANGIOGRAPHY, Male, IMPACT, Settore MED/18 - CHIRURGIA GENERALE, medicine.medical_treatment, Jejunostomy, Hepatic Duct, Common, Comorbidity, 030230 surgery, 0302 clinical medicine, Cholangiography, Older patients, Hepatic Duct, Clinical endpoint, LAPAROSCOPIC CHOLECYSTECTOMY, COMPLICATIONS, OUTCOMES, medicine.diagnostic_test, Bile duct, Gastroenterology, Hepaticojejunostomy, Middle Aged, Common, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Bile duct injuries (BDI), CLASSIFICATION, Time-to-Treatment, Biliary injury, 03 medical and health sciences, Sex Factors, HEPATIC-ARTERY INJURY, medicine, MANAGEMENT, Humans, Cholecystectomy, Aged, Retrospective Studies, Hepatology, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, BILIARY INJURY, Surgery, Multi center study, Concomitant, RISK-FACTORS, Human medicine, Bile Ducts, business
Abstract

13th World Biennial Congress of the International-Hepato-Pancreato-Biliary-Association (IHPBA) -- SEP 04-07, 2018 -- Geneva, SWITZERLAND, Ardito, Francesco/0000-0003-1596-2862; PESCE, ANTONIO MD/0000-0002-7560-551X; Gallagher, Tom/0000-0002-5765-2574; Bernon, Marc/0000-0002-7967-8548; Stattner, Stefan/0000-0002-5226-7597; GIULIANTE, FELICE/0000-0003-2087-2589; Omoshoro-Jones, Jones A. O./0000-0002-1071-298X; de Rose, Agostino Maria/0000-0003-3310-8088; Abu Hilal, Mohammed/0000-0002-3162-4639; Kleeff, Jorg/0000-0003-3432-6669; Prieto, Mikel/0000-0001-6662-4252; Stromberg, Cecilia/0000-0003-0843-7920, WOS: 000500283700006, PubMed: 31151812, Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. the aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0-7), intermediate (1-6 weeks) and late (6 weeks-6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: in total 913 patients from 48 centers were included in the analysis. in 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. in multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. the rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37-8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable., Int Hepato Pancreato Biliary Assoc

Published
2019
Full Text
View/download PDF

2. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

Author

Mazzaferro, V, Llovet, Jm, Miceli, R, Bhoori, S, Schiavo, M, Mariani, L, Camerini, T, Roayaie, S, Schwartz, Me, Grazi, Gl, Adam, R, Neuhaus, P, Salizzoni, M, Bruix, J, Forner, A, De Carlis, L, Cillo, U, Burroughs, Ak, Troisi, R, Rossi, M, Gerunda, Ge, Lerut, J, Belghiti, J, Boin, I, Gugenheim, J, Rochling, F, Van Hoek, B, Majno, P, Graziadei, I, Vogel, W, Lucidi, V, de Hemptinne, B, Leopardi, L, Cotsoglou, C, Iannelli, A, Staccini, A, Koenigsrainer, A, Steurer, W, Cautero, N, Risaliti, A, Lupo, L, Colledan, M, De Giorgio, M, Fagiuoli, S, Pinna, Ad, Ravaioli, M, Battiston, C, Coppa, J, Regalia, E, Romito, R, Giacomoni, A, Mangoni, J, Maggi, U, Rossi, G, Masetti, M, Montalti, R, Calise, F, Cuomo, O, Scuderi, E, Bridda, A, Vitale, A, Tisone, G, Berloco, P, Paraluppi, G, Patrono, D, Adani, Gl, Baccarani, U, Lorenzin, D, Zieniewicz, K, Ribeiro, V, Soderdahl, G, Giostra, E, Mentha, G, Morel, P, Marelli, L, Patch, D, Muiesan, P, Heaton, N, Schwartz, M, Rossaro, L, Khatri, V, Hsieh, Cb., Mazzaferro, V, Llovet, J, Miceli, R, Bhoori, S, Schiavo, M, Mariani, L, Camerini, T, Roayaie, S, Schwartz, M, Grazi, G, Adam, R, Neuhaus, P, Salizzoni, M, Bruix, J, Forner, A, De Carlis, L, Cillo, U, Burroughs, A, Troisi, R, Rossi, M, Gerunda, G, Lerut, J, Belghiti, J, Boin, I, Gugenheim, J, Rochling, F, Van Hoek, B, Majno, P, Colledan, M, Fagiuoli, S, Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M.E., Grazi G.L., Adam R., Neuhaus P., Salizzoni M., Bruix J., Forner A., De Carlis L., Cillo U., Burroughs A.K., Troisi R., Rossi M., Gerunda G.E., Lerut J., Belghiti J., Boin I., Gugenheim J., Rochling F., Van Hoek B., Majno P., Graziadei I., Vogel W., Lucidi V., de Hemptinne B., Leopardi L., Cotsoglou C., Iannelli A., Staccini A., Koenigsrainer A., Steurer W., Cautero N., Risaliti A., Lupo L., Colledan M., De Giorgio M., Fagiuoli S., Pinna A.D., Ravaioli M., Battiston C., Coppa J., Regalia E., Romito R., Giacomoni A., Mangoni J., Maggi U., Rossi G., Masetti M., Montalti R., Calise F., Cuomo O., Scuderi E., Bridda A., Vitale A., Tisone G., Berloco P., Paraluppi G., Patrono D., Adani G.L., Baccarani U, Lorenzin D, Zieniewicz K, Ribeiro V, Soderdahl G., Giostra E., Mentha G., Morel P., Marelli L., Patch D., Muiesan P., Heaton N., Rossaro L., Khatri V., Hsieh C.B., Mazzaferro, Vincenzo, Llovet, Josep M, Miceli, Rosalba, Bhoori, Sherrie, Schiavo, Marcello, Mariani, Luigi, Camerini, Tiziana, Roayaie, Sasan, Schwartz, Myron E, Grazi, Gian Luca, Adam, René, Neuhaus, Peter, Salizzoni, Mauro, Bruix, Jordi, Forner, Alejandro, De Carlis, Luciano, Cillo, Umberto, Burroughs, Andrew K, Troisi, Roberto, Rossi, Massimo, Gerunda, Giorgio E, Lerut, Jan, Belghiti, Jacque, Boin, Ilka, Gugenheim, Jean, Rochling, Fedja, Van Hoek, Bart, and Majno, Pietro

Subjects
Oncology, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Adolescent, medicine.medical_treatment, education, Liver transplantation, Milan criteria, Retrospective Studie, Liver Neoplasms/mortality/*surgery, Internal medicine, Liver Transplantation, Carcinoma, medicine, Humans, HEPATOCELLULAR CARCINOMA, Child, Aged, Retrospective Studies, mortality/surgery, ddc:617, Proportional hazards model, business.industry, Hazard ratio, Liver Neoplasms, SELECTION CRITERIA, Retrospective cohort study, Hepatocellular, Middle Aged, medicine.disease, digestive system diseases, Surgery, Carcinoma, Hepatocellular/mortality/*surgery, Transplantation, Settore MED/18 - Chirurgia Generale, Liver Neoplasm, Hepatocellular carcinoma, Adolescent, Adult, Aged, Carcinoma, mortality/surgery, Child, Humans, Liver Neoplasms, mortality/surgery, Liver Transplantation, Middle Aged, Retrospective Studies, business, Human
Abstract

Background: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour ≤5 cm in size or ≤3 tumours each ≤3 cm in size, and no macrovascular invasion) have an excellent outcome. However, survival for patients with cancers that exceed these criteria remains unpredictable and access to transplantation is a balance of maximising patients' chances of cure and organ availability. The aim of this study was to explore the survival of patients with tumours that exceed the Milan criteria, to assess whether the criteria could be less restrictive, enabling more patients to qualify as transplant candidates, and to derive a prognostic model based on objective tumour characteristics, to see whether the Milan criteria could be expanded. Methods: Data on patients who underwent transplantation for hepatocellular carcinoma despite exceeding Milan criteria at different centres were recorded via a web-based survey completed by specialists from each centre. The survival of these patients was correlated retrospectively with the size of the largest tumour nodule, number of nodules, and presence or absence of microvascular invasion detected at pathology. Contoured multivariable regression Cox models produced survival estimates by means of different combinations of the covariates. The primary aim of this study was to derive a prognostic model of overall survival based on tumour characteristics, according to the main parameters used in the Tumour Node Metastasis classification. The secondary aim was the identification of a subgroup of patients with hepatocellular carcinoma exceeding the Milan criteria, who achieved a 5-year overall survival of at least 70%-ie, similar to the outcome expected for patients who meet the Milan criteria. Findings: Over a 10-month period, between June 25, 2006, and April 3, 2007, data for 1556 patients who underwent transplantation for hepatocellular carcinoma were entered on the database by 36 centres. 1112 patients had hepatocellular carcinoma exceeding Milan criteria and 444 patients had hepatocellular carcinoma shown not to exceed Milan criteria at post-transplant pathology review. In the group of patients with hepatocellular carcinomas exceeding the criteria, the median size of the largest nodule was 40 mm (range 4-200) and the median number of nodules was four (1-20). 454 of 1112 patients (41%) had microvascular invasion and, for those transplanted outside the Milan criteria, 5-year overall survival was 53·6% (95% CI 50·1-57·0), compared with 73·3% (68·2-77·7) for those that met the criteria. Hazard ratios (HR) associated with increasing values of size and number were 1·34 (1·25-1·44) and 1·51 (1·21-1·88), respectively. The effect was linear for size, whereas for number of tumours, the effect tended to plateau above three tumours. The effect of tumour size and number on survival was mediated by recurrence (b=0·08, SE=0·12, p=0·476). The presence of microvascular invasion doubled HRs in all scenarios. The 283 patients without microvascular invasion, but who fell within the Up-to-seven criteria (hepatocellular carcinomas with seven as the sum of the size of the largest tumour [in cm] and the number of tumours) achieved a 5-year overall survival of 71·2% (64·3-77·0). Interpretation: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual (yes/no) approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria. Funding: Specific funding was not used to do this study. © 2009 Elsevier Ltd. All rights reserved

Published
2009

3. Liver graft bile duct necrosis--indication for retransplantation

Author

Nyckowski, P., Krawczyk, M., Zieniewicz, K., Najnigier, B., Patkowski, W., Gelo, R., Paczek, L., Butruk, E., Andrzej Habior, Bartnik, W., Tomecki, R., Wrzaszczyk, R., and Karwowski, A.

Subjects
Adult, Male, Reoperation, Necrosis, Retreatment, Humans, Female, Bile Ducts, Middle Aged, Liver Transplantation
Abstract

The authors describe the first in Poland case of liver retransplantation in an adult recipient, in whom the indication for the procedure was bile duct necrosis following liver transplantation due to liver cirrhosis of an uncertain origin.

Published
1997

4. [Complications of laparoscopic cholecystectomy]

Author

Najnigier B, Zieniewicz K, Nyckowski P, Fraczek M, Waldemar Patkowski, Wróblewski T, and Krawczyk M

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Cholecystectomy, Laparoscopic, Cholelithiasis, Humans, Female, Length of Stay, Middle Aged, Child, Aged
Abstract

Complications of laparoscopic cholecystectomy were evaluated in the group of 1.284 patients operated on from June 1991 to December 1996. Serious complications were observed in 38 (2.9%) patients. Conversion to open cholecystectomy was required in 50 patients, including 4 patients with common bile duct injury, 3 patients with bleeding from the gall bladder bed, 2 with cholecysto-duodenal fistula and 6 with intraperitoneal adhesions. In 35 patients the conversion was performed due to inflammatory changes in the Calot triangle. The authors did not observe any serious vascular injury as well as lethal complications. They conclude, that the correct indications to surgery and adequate surgical technique are the most important factors preventing the complications.

Published
1997

5. [Orthotopic liver transplantation in clinical materials]

Author

Pawlak J, Michałowicz B, Krawczyk M, Nyckowski P, Piotr Małkowski, Wróblewski T, Zieniewicz K, and Karwowski A

Subjects
Adult, Male, Reoperation, Survival Rate, Chronic Disease, Humans, Female, Liver Failure, Acute, Middle Aged, Liver Failure, Follow-Up Studies, Liver Transplantation
Abstract

The authors present their own experience in orthotopic liver transplantation as a treatment of acute and chronic liver failure. 18 transplantations were performed in 16 patients. The indications for transplantation: acute liver failure-3 cases, chronic advanced disease of the liver-13 cases, graft failure requiring retransplantation-2 cases. All 3 patients with acute failure died after transplantation. Out of 13 patients after elective transplantations 11 remain alive, (in this number both retransplanted). The longest follow-up period is 2.5 years.

Published
1997

6. [Complications after liver resection for benign lesions]

Author

Krawczyk M, Nyckowski P, Zieniewicz K, Najnigier B, Waldemar Patkowski, and Karwowski A

Subjects
Adult, Male, Cysts, Incidence, Liver Diseases, Liver Neoplasms, Middle Aged, Survival Rate, Postoperative Complications, Liver, Risk Factors, Hepatectomy, Humans, Female, Hemangioma
Abstract

The paper presents the results of 76 hepatic resection in the group of patients with benign liver lesions. The most common indication to the resection were liver cysts and hemangioma. Morbidity occurred in 13% of patients. After liver trauma the highest mortality we observed.

Published
1997

7. [Orthotopic liver transplantation in a patient with primary biliary cirrhosis]

Author

Pawlak J, Piotr Małkowski, Michałowicz B, Zieniewicz K, Nyckowski P, Grzelak I, Schaeffer M, Gackowski W, Karwowski A, and Lao M

Subjects
Liver Cirrhosis, Biliary, Humans, Female, Middle Aged, Prognosis, Liver Transplantation
Abstract

In December 1994 an orthotopic liver transplantation was performed in a 46-year old female patient with liver failure due to primary biliary cirrhosis. The patient was discharged on the 31-st postoperative day. The graft was obtained at the multi-organ harvesting. The results of the donor's biochemical tests and the histological estimation of the graft tissue allowed to prognose a successful postoperative course.

Published
1995

9. [Surgical treatment of biliary tract neoplasms]

Author

Waldemar Patkowski, Krawczyk M, Zieniewicz K, Nyckowski P, Pawlak J, and Karwowski A

Subjects
Adult, Cholangiocarcinoma, Male, Bile Ducts, Intrahepatic, Treatment Outcome, Adolescent, Bile Duct Neoplasms, Humans, Anastomosis, Roux-en-Y, Female, Middle Aged, Aged, Neoplasm Staging
Abstract

The authors present their own experiences concerning the treatment of the 34 patients with the benign and malignant tumors of the biliary tract. In the group of patients with malignant tumors, the type and extent of the surgery were dictated by the stage of the disease. Patients with benign tumors were subjected to resection of the region of bile duct bifurcation with Roux-Y hepaticojejunostomy.

11. Liver transplantation in the experience of the centre commencing the program

Author

Nyckowski, P., Krawczyk, M., Paczek, L., Kacka, A., Górnicka, B., Habior, A., Zieniewicz, K., Michałowicz, B., Pawlak, J., Małkowski, P., Paluszkiewicz, R., Grzelak, I., Patkowski, W., Najnigier, B., Tadeusz Wróblewski, Pszenny, C., Gackowski, W., Alsharabi, A., Fraczek, M., Szczerbań, J., Karwowski, A., Ołdakowska, U., Gradowska, L., Gelo, R., Siciśki, M., and Brudkowska, A.

Subjects
Reoperation, Survival Rate, Liver Diseases, Humans, Poland, Liver Transplantation, Retrospective Studies
Abstract

From 1989 to 1999, 43 orthotopic liver transplantations (OLT) in 40 patients (3 retransplantations) were performed in our Department. The most common indications for OLT were noninflammatory, primary cholestatic liver diseases and postinflammatory liver cirrhosis. Fourty OLT's were done for elective indications, three--on emergency basis, because of fulminant liver failure. The majority of transplantations was performed with classical technique with the excision of retrohepatic vena cava and routine use of the extracorporeal veno-venous bypass. Only in 4 patients the piggyback technique was used and performed without temporary portocaval anastomosis. All 3 patients transplanted for fulminant liver failure died in the perioperative period. Twenty four patients are still alive and well, the longest period of observation exceeding 5 years.

12. Technical aspects of orthotopic liver transplantation

Author

Nyckowski P, Karim Boudjema, Jaeck D, Wolf P, Zieniewicz K, and Krawczyk M

Subjects
Hepatic Artery, Duodenum, Portal Vein, Anastomosis, Surgical, Hepatectomy, Humans, Vena Cava, Inferior, Tissue Donors, Liver Transplantation

13. [Reconstructive surgery in iatrogenic bile duct injuries]

Author

Krawczyk M, Kania M, Zieniewicz K, Nyckowski P, Waldemar Patkowski, and Karwowski A

Subjects
Cholecystectomy, Laparoscopic, Iatrogenic Disease, Humans, Anastomosis, Roux-en-Y, Bile Ducts, Retrospective Studies
Abstract

The paper presents the results of surgical treatment performed in 54 patients with iatrogenic injury of biliary tract. All cases of injury were made during open and laparoscopic cholecystectomy. We concluded that Roux-en-Y hepatico-jejunostomy should be recommended. There were no deaths after surgery. This technic was successful therapeutic management more than 95% of cases.

14. Orthotopic liver transplantation for cholestatic diseases

Author

Patkowski, W., Michał Skalski, Zieniewicz, K., Nyckowski, P., Smoter, P., and Krawczyk, M.

Subjects
Adult, Male, Echinococcosis, Hepatic, Cholestasis, Cystic Fibrosis, Liver Cirrhosis, Biliary, Cholangitis, Sclerosing, Middle Aged, Severity of Illness Index, Caroli Disease, Liver Transplantation, Humans, Female, Aged, Retrospective Studies
Abstract

According to the data of the European Liver Transplant Registry (ELTR), liver transplantations (LTx) as a result of bile duct diseases were reported in 12.0% of cases. The aim of this study was to overview retrospective indications for operation and results of patients who underwent LTx for cholestatic diseases.725 LTx were performed between January 1989 to December 2008, including 173 (23.9%) patients with cholestatic diseases. 80 pts (46.2%) were operated because of PBC, 63 pts (36.4%) with PSC and 12 pts (6.9%) with SBC as a result of iatrogenic bile ducts injuries. In 6 pts (3.5%) Caroli's disease was the reason for transplantation and another 11 pts (6.4%) were operated because of infiltration of alveococcosis into the bile duct. Cholangiocarcinoma (CCC) developed in 6 pts with PSC (9.5%) undergoing LTx. The last patient (0.6%) of our group was operated because of mucoviscidosis. 24 pts (13.9%) underwent unsuccessful surgical treatment prior to the LTx.142 pts (82.1%) presented good outcome, but complications in postoperative period were present in 31 pts (17.9%). 8 pts (4.6%) required re-laparotomy: 6 pts due to intraperitoneal bleeding and hematoma in the first postoperative week and 2 pts due to liver abscess, 1 month and 3 months after LTx respectivelly. 4 patients (2.3%) died in the first week after LTx (septic complications, acute rejection). 5 patients with CCC died in the period of 7 to 26 months after LTx. This was caused by the recurrence of the cancer. The overall mortality was 8.1% (14 pts). 4 pts (2.3%) underwent ReLTx due to various origins--one case due to hepatic artery thrombosis, another was ischemic type biliary lesion (ITBL) and two patients due to recurrence of PBC and PSC. Cumulative 1, 5 and 10 year recurrence-free survival rates after LTx were: 94.6% / 88.7% / 72.1% in PBC group, 95.3% / 86.5% / 70.2% in PSC group and 73.9% / 69.2% / 59.3% in SBC group of patients.There is no doubt that LTx is a good and effective option of treatment for patients with cholestatic diseases. Nevertheless the long-term benefits of LTx depend on precise indications and timing of the operation.

15. COVID-19 in liver transplant candidates

Author

Belli, Luca Saverio, Duvoux, Christophe, Cortesi, Paolo Angelo, Facchetti, Rita, Iacob, Speranta, Perricone, Giovanni, Radenne, Sylvie, Conti, Sara, Patrono, Damiano, Berlakovich, Gabriela, Hann, Angus, Pasulo, Luisa, Castells, Lluis, Faitot, Francois, Detry, Olivier, Invernizzi, Federica, Magini, Giulia, De Simone, Paolo, Kounis, Ilias, Morelli, Maria Cristina, Díaz Fontenla, Fernando, Ericzon, Bo-Göran, Loinaz, Carmelo, Johnston, Chris, Gheorghe, Liliana, Lesurtel, Mickael, Romagnoli, Renato, Kollmann, Dagmar, Perera, M Thamara Pr, Fagiuoli, Stefano, Mirza, Darius, Coilly, Audrey, Toso, Christian, Zieniewicz, Krzysztof, Elkrief, Laure, Karam, Vincent, Adam, Rene, den Hoed, Caroline, Merli, Marco, Puoti, Massimo, De Carlis, Luciano, Oniscu, Gabriel C, Piano, Salvatore, Angeli, Paolo, Fondevila, Constantino, Polak, Wojciech G, ELITA-ELTR COVID-19 Registry, Gastroenterology & Hepatology, Surgery, Belli, L, Duvoux, C, Cortesi, P, Facchetti, R, Iacob, S, Perricone, G, Radenne, S, Conti, S, Patrono, D, Berlakovich, G, Hann, A, Pasulo, L, Castells, L, Faitot, F, Detry, O, Invernizzi, F, Magini, G, De Simone, P, Kounis, I, Morelli, M, Diaz Fontenla, F, Ericzon, B, Loinaz, C, Johnston, C, Gheorghe, L, Lesurtel, M, Romagnoli, R, Kollmann, D, Perera, M, Fagiuoli, S, Mirza, D, Coilly, A, Toso, C, Zieniewicz, K, Elkrief, L, Karam, V, Adam, R, Den Hoed, C, Merli, M, Puoti, M, De Carlis, L, Oniscu, G, Piano, S, Angeli, P, Fondevila, C, and Polak, W

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Waiting Lists, medicine.medical_treatment, liver cirrhosis, Pneumonia, Viral, Population, Liver transplantation, 03 medical and health sciences, Liver disease, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, Cause of Death, Medicine, Humans, Viral, Registries, education, Cause of death, education.field_of_study, ddc:617, liver transplantation, liver cirrhosi, Proportional hazards model, business.industry, SARS-CoV-2, Gastroenterology, COVID-19, Pneumonia, Middle Aged, medicine.disease, Transplant Recipients, Transplantation, Europe, 030104 developmental biology, Respiratory failure, Liver cirrhosis, 030211 gastroenterology & hepatology, Female, Liver Transplantation, business, Cohort study
Abstract

ObjectiveExplore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course.DesignData from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed.ResultsFrom 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170).ConclusionsIncreased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

Published
2021

16. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)

Author

Luca S. Belli, Christophe Duvoux, Thierry Artzner, William Bernal, Sara Conti, Paolo A. Cortesi, Sophie-Caroline Sacleux, George-Philippe Pageaux, Sylvie Radenne, Jonel Trebicka, Javier Fernandez, Giovanni Perricone, Salvatore Piano, Silvio Nadalin, Maria C. Morelli, Silvia Martini, Wojciech G. Polak, Krzysztof Zieniewicz, Christian Toso, Marina Berenguer, Claudia Iegri, Federica Invernizzi, Riccardo Volpes, Vincent Karam, René Adam, François Faitot, Liane Rabinovich, Faouzi Saliba, Lucy Meunier, Mickael Lesurtel, Frank E. Uschner, Costantino Fondevila, Baptiste Michard, Audrey Coilly, Magdalena Meszaros, Domitille Poinsot, Andreas Schnitzbauer, Luciano G. De Carlis, Roberto Fumagalli, Paolo Angeli, Vincente Arroyo, Rajiv Jalan, Raffaella Viganò, Chiara Mazzarelli, Andrea Lauterio, Alessandro Giacomoni, Francesca Donato, Pietro Lampertico, Luisa Pasulo, Stefano Fagiuoli, Michele Colledan, Maria Cristina Morelli, Giovanni Vitale, Damiano Patrono, Renato Romagnoli, Antonio Ottobrelli, Ioannis Petridis, Umberto Cillo, Giacomo Germani, Patrizia Burra, Philippe Bachellier, Pietro Addeo, Camille Besch, Francoise Faitot, Sophie Caroline Sacleux, Saliba Faouzi, Rene Adam, Didier Samuel, Celine Guichon, Stéfanie Faure, Josè Ursic-Bedoya, Jorde Colmenero, David Toapanta, María Hernández-Tejero, Carmen Vinaixa, Caroline den Hoed, Jubi E. de Haan, Andrea Della Penna, Frank Erhard Uschner, Martin Welker, Stefan Zeuzem, Wolf Bechstein, Nicolas Goossens, Joanna Raszeja-Wyszomirska, Dev Katarey, Banwari Agarwal, Surgery, Internal Medicine, Gastroenterology & Hepatology, Intensive Care, ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia], Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital de Hautepierre [Strasbourg], King‘s College London, Ospedale Multimedica Sesto San Giovanni, Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Goethe-University Frankfurt am Main, European Foundation for Study of Chronic Liver Failure [Barcelona] (EF CLIF), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Azienda Ospedaliero-Universitaria di Bologna, Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Medical University of Warsaw - Poland, Geneva University Hospitals and Geneva University, Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe, Hospital Papa Giovanni XXIII (Hosp P Giovanni XXIII), Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), Pôle des Pathologies Digestives Hépatiques et Transplantation [Hôpital Hautepierre-Strasbourg], Department of Physiopatology and Transplantation, University of Milan (DEPT), Università degli Studi di Milano = University of Milan (UNIMI), Ospedale S. Giovanni Battista-Molinette, Azienda Ospedaliera di Padova, Università degli Studi di Padova = University of Padua (Unipd), Hospital Clinic i Provincial de Barcelona (SCReN), University College London Hospitals (UCLH), Belli, L, Duvoux, C, Artzner, T, Bernal, W, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinovich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Fondevila, C, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Jalan, R, Fagiuoli, S, Goossens, Nicolas, and Salvy-Córdoba, Nathalie

Subjects
Male, 0301 basic medicine, Multi-drug resistant organisms, medicine.medical_treatment, Waiting list, Salvage therapy, Liver transplantation, Severity of Illness Index, MESH: Proportional Hazards Models, Cohort Studies, 0302 clinical medicine, MESH: Risk Factors, Risk Factors, Medicine, MESH: Cohort Studies, Acute-on-Chronic Liver Failure, MESH: Aged, High rate, MESH: Middle Aged, ddc:617, Hazard ratio, MESH: Acute-On-Chronic Liver Failure, Middle Aged, Prognosis, Predictive factors, Italy, Female, 030211 gastroenterology & hepatology, Adult, MESH: Liver Transplantation, medicine.medical_specialty, MESH: Prognosis, 03 medical and health sciences, MESH: Severity of Illness Index, Internal medicine, Humans, Acute on chronic liver failure, Renal replacement therapy, Aged, Proportional Hazards Models, Retrospective Studies, MESH: Humans, Hepatology, business.industry, MESH: Italy, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Retrospective cohort study, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Multi-drug resistant organism, MESH: Male, 030104 developmental biology, Predictive factor, business, MESH: Female
Abstract

Background & Aims: Liver transplantation (LT) has been proposed as an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was designed to assess the current clinical practice and outcomes of patients with ACLF who are wait-listed for LT in Europe. Methods: This was a retrospective study including 308 consecutive patients with ACLF, listed in 20 centres across 8 European countries, from January 2018 to June 2019. Results: A total of 2,677 patients received a LT: 1,216 (45.4%) for decompensated cirrhosis. Of these, 234 (19.2%) had ACLF at LT: 58 (4.8%) had ACLF-1, 78 (6.4%) had ACLF-2, and 98 (8.1%) had ACLF-3. Wide variations were observed amongst countries: France and Germany had high rates of ACLF-2/3 (27-41%); Italy, Switzerland, Poland and the Netherlands had medium rates (9-15%); and the United Kingdom and Spain had low rates (3-5%) (p 4 mmol/L (hazard ratio [HR] 3.14; 95% CI 1.37-7.19), recent infection from multidrug resistant organisms (HR 3.67; 95% CI 1.63-8.28), and renal replacement therapy (HR 2.74; 95% CI 1.37-5.51) were independent predictors of post-LT mortality. During the same period, 74 patients with ACLF died on the waiting list. In an intention-to-treat analysis, 1-year survival of patients with ACLF on the LT waiting list was 73% for ACLF-1 or-2 and 50% for ACLF-3. Conclusion: The results reveal wide variations in the listing of patients with ACLF in Europe despite favourable post-LT survival. Risk factors for mortality were identified, enabling a more pre-cise prognostic assessment of patients with ACLF. Lay summary: Acute-on-chronic liver failure (ACLF) is a severe clinical condition for which liver transplantation is an effective therapeutic option. This study has demonstrated that in Europe, referral and access to liver transplantation (LT) for patients with ACLF needs to be harmonised to avoid inequities. Post-LT survival for patients with ACLF was >80% after 1 year and some factors have been identified to help select patients with favourable outcomes. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All reserved.

Published
2021
Full Text
View/download PDF

17. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study

Author

Adam, René, Karam, Vincent, Cailliez, Valérie, Trunečka, Pavel, Samuel, Didier, Tisone, Giuseppe, Němec, Petr, Soubrane, Olivier, Schneeberger, Stefan, Gridelli, Bruno, Bechstein, Wolf O., Risaliti, Andrea, Line, Pal-Dag, Vivarelli, Marco, Rossi, Massimo, Pirenne, Jacques, Klempnauer, Jurgen L., Rummo, Aleh, Di Benedetto, Fabrizio, Zieniewicz, Krzysztof, Troisi, Roberto, Paul, Andreas, Vali, Toomas, Kollmar, Otto, Boudjema, Karim, Hoti, Emir, Colledan, Michele, Pratschke, Johan, Lang, Hauke, Popescu, Irinel, Ericzon, Bo-Goran, Strupas, Kestutis, De Simone, Paolo, Kochs, Eberhard, Heyd, Bruno, Gugenheim, Jean, Pinna, Antonio D., Bennet, William, Kazimi, Mirjalal, Bachellier, Philippe, Wigmore, Stephen J., Rasmussen, Allan, Clavien, Pierre-Alain, Hidalgo, Ernest, O'Grady, John G., Zamboni, Frausto, Kilic, Murat, Duvoux, Christophe, O’Grady, John G., Adam, R, Karam, V, Cailliez, V, Trunecka, P, Samuel, D, Tisone, G, Nemec, P, Soubrane, O, Schneeberger, S, Gridelli, B, Bechstein, W, Risaliti, A, Line, P, Vivarelli, M, Rossi, M, Pirenne, J, Klempnauer, J, Rummo, A, Di Benedetto, F, Zieniewicz, K, Troisi, R, Paul, A, Vali, T, Kollmar, O, Boudjema, K, Hoti, E, Colledan, M, Pratschke, J, Lang, H, Popescu, I, Ericzon, B, Strupas, K, De Simone, P, Kochs, E, Heyd, B, Gugenheim, J, Pinna, A, Bennet, W, Kazimi, M, Bachellier, P, Wigmore, S, Rasmussen, A, Clavien, P, Hidalgo, E, O'Grady, J, Zamboni, F, Kilic, M, and Duvoux, C

Subjects
Graft Rejection, Male, medicine.medical_specialty, Time Factors, Drug Compounding, medicine.medical_treatment, Calcineurin Inhibitors, Medizin, MEDLINE, chemical and pharmacologic phenomena, Liver Transplant, 030230 surgery, Liver transplantation, Risk Assessment, Tacrolimus, all contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA), 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Prolonged release, Internal medicine, medicine, Humans, Aged, Delayed-Action Preparations, Europe, Female, Graft Survival, Immunosuppressive Agents, Middle Aged, Registries, Retrospective Studies, Treatment Outcome, Liver Transplantation, Transplantation, business.industry, Immunosuppression, Retrospective cohort study, Settore MED/18, 3. Good health, surgical procedures, operative, 030211 gastroenterology & hepatology, Transplant patient, business, Risk assessment
Abstract

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with

Published
2019
Full Text
View/download PDF

18. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation

Author

Adam, René, Karam, Vincent, Cailliez, Valérie, O Grady, John G, Mirza, Darius, Cherqui, Daniel, Klempnauer, Jurgen, Salizzoni, Mauro, Pratschke, Johann, Jamieson, Neville, Hidalgo, Ernest, Paul, Andreas, Andujar, Rafael Lopez, Lerut, Jan, Fisher, Lutz, Boudjema, Karim, Fondevila, Constantino, Soubrane, Olivier, Bachellier, Philippe, Pinna, Antonio D, Berlakovich, Gabriela, Bennet, William, Pinzani, Massimo, Schemmer, Peter, Zieniewicz, Krzysztof, Romero, Carlos Jimenez, De Simone, Paolo, Ericzon, Bo-Goran, Schneeberger, Stefan, Wigmore, Stephen J, Prous, Joan Fabregat, Colledan, Michele, Porte, Robert J, Yilmaz, Sezai, Azoulay, Daniel, Pirenne, Jacques, Line, Pal-Dag, Trunecka, Pavel, Navarro, Francis, Lopez, Andres Valdivieso, De Carlis, Luciano, Pena, Sebastian Rufian, Kochs, Eberhard, Duvoux, Christophe, all the other 126 contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA), Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Modèles de Cellules Souches Malignes et Thérapeutiques, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Strasbourg, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Groningen Institute for Organ Transplantation (GIOT), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Adam, R, Karam, V, Cailliez, V, O Grady, J, Mirza, D, Cherqui, D, Klempnauer, J, Salizzoni, M, Pratschke, J, Jamieson, N, Hidalgo, E, Paul, A, Andujar, R, Lerut, J, Fisher, L, Boudjema, K, Fondevila, C, Soubrane, O, Bachellier, P, Pinna, A, Berlakovich, G, Bennet, W, Pinzani, M, Schemmer, P, Zieniewicz, K, Romero, C, De Simone, P, Ericzon, B, Schneeberger, S, Wigmore, S, Prous, J, Colledan, M, Porte, R, Yilmaz, S, Azoulay, D, Pirenne, J, Line, P, Trunecka, P, Navarro, F, Lopez, A, De Carlis, L, Pena, S, Kochs, E, Duvoux, C, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
Male, Registry study, medicine.medical_treatment, Medizin, Disease, 030230 surgery, Liver transplantation, registry, Single Center, DISEASE, Hemangioendothelioma, Outcome, Registry, 0302 clinical medicine, Surveys and Questionnaires, HEPATOCELLULAR-CARCINOMA, Epidemiology, Prospective Studies, Registries, Child, Geography, liver transplantation, Liver Diseases, liver transplantation, outcome, registry, Graft Survival, Liver Neoplasms, Annual report, Middle Aged, Tissue Donors, 3. Good health, Europe, Hepatocellular carcinoma, SURVIVAL, outcome, 030211 gastroenterology & hepatology, Female, Adult, Reoperation, medicine.medical_specialty, Adolescent, PLACE, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Time-to-Treatment, 03 medical and health sciences, Young Adult, QUALITY-CONTROL, medicine, Humans, Aged, Transplantation, business.industry, General surgery, MORTALITY, GRAFT, medicine.disease, HEMANGIOENDOTHELIOMA, CENTERS, EXPERIENCE, business
Abstract

The purpose of this registry study was to provide an overview of trends and results of liver transplantation (LT) in Europe from 1968 to 2016. These data on LT were collected prospectively from 169 centers from 32 countries, in the European Liver Transplant Registry (ELTR) beginning in 1968. This overview provides epidemiological data, as well as information on evolution of techniques, and outcomes in LT in Europe over more than five decades; something that cannot be obtained from only a single center experience. ispartof: TRANSPLANT INTERNATIONAL vol:31 issue:12 pages:1293-1317 ispartof: location:Switzerland status: published

Published
2018
Full Text
View/download PDF

19. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Beata, Kos-Kudła, Jolanta, Blicharz-Dorniak, Janusz, Strzelczyk, Agata, Bałdys-Waligórska, Tomasz, Bednarczuk, Marek, Bolanowski, Agnieszka, Boratyn-Nowicka, Małgorzata, Borowska, Andrzej, Cichocki, Jarosław B, Ćwikła, Massimo, Falconi, Wanda, Foltyn, Daria, Handkiewicz-Junak, Alicja, Hubalewska-Dydejczyk, Barbara, Jarząb, Roman, Junik, Dariusz, Kajdaniuk, Grzegorz, Kamiński, Agnieszka, Kolasińska-Ćwikła, Aldona, Kowalska, Robert, Król, Leszek, Królicki, Maciej, Krzakowski, Jolanta, Kunikowska, Katarzyna, Kuśnierz, Paweł, Lampe, Dariusz, Lange, Anna, Lewczuk-Myślicka, Andrzej, Lewiński, Michał, Lipiński, Magdalena, Londzin-Olesik, Bogdan, Marek, Anna, Nasierowska-Guttmejer, Sergiusz, Nawrocki, Ewa, Nowakowska-Duława, Joanna, Pilch-Kowalczyk, Violetta, Rosiek, Marek, Ruchała, Lucyna, Siemińska, Anna, Sowa-Staszczak, Teresa, Starzyńska, Katarzyna, Steinhof-Radwańska, Krzysztof, Sworczak, Anhelli, Syrenicz, Andrzej, Szawłowski, Marek, Szczepkowski, Ewa, Wachuła, Wojciech, Zajęcki, Anna, Zemczak, Wojciech, Zgliczyński, Krzysztof, Zieniewicz, Kos-Kudla, B., Blicharz-Dorniak, J., Strzelczyk, J., Baldys-Waligorska, A., Bednarczuk, T., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Foltyn, W., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Krzakowski, M., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Lipinski, M., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nawrocki, S., Nowakowska-Dulawa, E., Pilch-Kowalczyk, J., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zemczak, A., Zgliczynski, W., and Zieniewicz, K.

Subjects
Male, Gastro-entero-pancreatic neuroendocrine neoplasms, Disease Management, Medical Oncology, Pancreatic Neoplasms, Neuroendocrine Tumors, Endocrinology, Diagnosis, Humans, Female, Therapy, Poland, Societies, Medical, Gastrointestinal Neoplasms
Abstract

Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference - Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommenda-tions, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results